Avalo Therapeutics, Inc.: directors' dealings · United States · SEC (Form 4)

About Avalo Therapeutics, Inc.

Avalo Therapeutics, Inc. (NASDAQ: AVTX) is a U.S.-listed clinical-stage biopharmaceutical company focused on immune-mediated inflammatory diseases. For French, Belgian, and Swiss investors, Avalo should be viewed as a small-cap biotech with no mature commercial franchise yet, and therefore a company whose investment case is primarily driven by clinical execution, regulatory milestones, and financing capacity rather than near-term sales. The company is headquartered in the United States, in Wayne (Chesterbrook), Pennsylvania. Its current strategy is highly focused: Avalo says it is fully dedicated to therapies targeting the IL-1β pathway, a key inflammatory signaling axis. Its lead asset is abdakibart (AVTX-009), an anti-IL-1β monoclonal antibody currently being evaluated in a Phase 2 trial in hidradenitis suppurativa (HS), a chronic inflammatory skin disease with substantial unmet medical need. Avalo’s history shows a clear strategic transformation. The business previously operated under the name Cerecor Inc. and adopted the Avalo Therapeutics name in August 2021 to reflect a stronger emphasis on immunology and diseases with significant unmet therapeutic need. Company disclosures also indicate that Avalo completed a merger with Aevi Genomic Medicine in February 2020, which helped reshape the pipeline and the company’s clinical identity. Over the past several years, Avalo has been streamlining its portfolio and concentrating resources on its lead program, a common approach among development-stage biotech companies seeking to maximize the probability of a meaningful clinical readout. Operationally, Avalo does not yet market any approved products. Its business model is based on research, clinical development, and, if successful, regulatory approval followed by eventual commercialization or partnering. The company is also exploring whether abdakibart could be expanded into additional inflammatory indications where unmet need remains high. From a competitive standpoint, Avalo is not positioned as a broad-based pharmaceutical player; rather, it is a focused innovation vehicle competing on scientific differentiation, trial data, and the potential breadth of the IL-1β mechanism. That said, its narrow asset concentration also creates a pronounced binary-risk profile. Recent developments are material. Avalo reported positive Phase 2 topline data for abdakibart in HS, released its first-quarter 2026 financial results, and announced on May 5, 2026 the pricing of a $375 million public offering. In practical terms, that financing event should strengthen the company’s near-term operating runway and support ongoing clinical development. Overall, AVTX remains a high-risk, catalyst-driven biotech story listed on the NASDAQ in the United States, with valuation likely to remain highly sensitive to future trial outcomes, regulatory progress, and capital-market conditions.